share_log

CENTOGENE Receives Delisting Notice From Nasdaq, Effective At The Open Of Trading On August 8, 2024

CENTOGENE Receives Delisting Notice From Nasdaq, Effective At The Open Of Trading On August 8, 2024

centogene收到納斯達克的退市通知,自2024年8月8日交易開市起生效。
Benzinga ·  08/07 17:25

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE'S common stock from Nasdaq. The notice indicates that CENTOGENE (the "Company") remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares.

作爲罕見病與神經退行性疾病數據驅動答案的重要生命科學合作伙伴,Centogene N.V.今天宣佈,它收到了納斯達克證券交易所("Nasdaq")的通知,指示納斯達克聽證會已決定從納斯達克除牌CENTOGENE的普通股。該通知指出,公司CENTOGENE仍未遵守納斯達克上市規則5450(b)(2)(C),該規則要求公開持股的最小市值爲1500萬美元。

Suspension of trading in the Company's common stock on Nasdaq will be effective at the open of trading on August 8, 2024. The Company may, within 15 calendar days from the date of the notice, request that Nasdaq review the decision, but the Company does not intend to make such a request.

公司的普通股在納斯達克停牌的時間將從2024年8月8日交易開始時生效。公司在通知日期起15個日曆日內可以請求納斯達克審查該決定,但公司沒有這樣的意向。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論